Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Silk Road Medical Reports Third Quarter 2021 Financial Results

November 9, 2021 GMT

SUNNYVALE, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the quarter ended September 30, 2021.

“I am incredibly proud of our team for continuing to drive TCAR adoption forward against the headwinds of the pandemic,” said Erica Rogers, President and Chief Executive Officer of Silk Road Medical. “We are investing confidently in the people and programs that will drive our growth in 2022 and beyond. We remain as committed as ever to establishing TCAR as the new standard of care in carotid artery disease.”

Third Quarter 2021 Financial Results
Revenue for the third quarter of 2021 was $24.7 million, an increase of $4.6 million or 23%, compared to the third quarter of 2020.

Gross profit for the third quarter of 2021 was $18.6 million compared to $14.6 million for the third quarter of 2020. Gross margin for the third quarter of 2021 increased to 75% compared to 73% in the third quarter of 2020. Gross margin in the prior year period included unfavorable production variances as a result of temporarily idled manufacturing operations and lower than anticipated demand due to COVID-19.


Operating expenses were $31.9 million for the third quarter of 2021, compared to $23.9 million in the corresponding prior year period, which represents an increase of 33%. The increase was driven by investment in new and ongoing R&D programs, as well as continued expansion of our sales team and commercial efforts, and general corporate and other costs.

Net loss was $13.9 million in the third quarter of 2021, or a loss of $0.40 per share, as compared to a loss of $10.3 million, or $0.31 per share, in the corresponding period of the prior year.

Cash, cash equivalents, and short-term investments were $122.8 million as of September 30, 2021.

2021 Financial Guidance
Based on unforeseen impacts from the COVID-19 delta variant, Silk Road Medical now projects revenue for the full year 2021 to range from $99 million to $102 million, which represents 32% to 36% growth over the company’s prior year revenue.

Conference Call
Silk Road Medical will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 9, 2021 to discuss its third quarter 2021 financial results. The call may be accessed through an operator by dialing (844) 883-3861 for domestic callers or (574) 990-9820 for international callers, using conference ID: 3998078. A live and archived webcast of the event will be available at


About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit and connect on Twitter, LinkedIn and Facebook.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These statements include statements regarding the impact of COVID-19 on our business, financial guidance, progress made on achieving our corporate goals, and the overall strength of our business and culture. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our filing made with the Securities and Exchange Commission in Silk Road’s Quarterly Report on Form 10-Q filing made with the Securities and Exchange Commission on August 6, 2021. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Silk Road Medical disclaims any obligation to update these forward-looking statements.

Investor Contact:
Lynn Lewis or Marissa Bych
Gilmartin Group

Michael Fanucchi
Silk Road Medical

Statements of Operations Data
(Unaudited, in thousands, except share and per share data)
        Three Months Ended
September 30,
  Nine Months Ended
September 30,
        2021   2020   2021   2020 
Revenue  $24,701  $20,067  $73,210  $54,093 
Cost of goods sold  6,076   5,488   18,213   16,074 
     Gross profit  18,625   14,579   54,997   38,019 
Operating expenses:        
 Research and development  6,867   4,711   19,611   11,232 
 Selling, general and administrative  25,049   19,202   68,792   54,652 
     Total operating expenses  31,916   23,913   88,403   65,884 
     Loss from operations  (13,291)  (9,334)  (33,406)  (27,865)
Interest income  42   249   183   951 
Interest expense  (633)  (1,215)  (1,884)  (3,620)
Other income (expense), net  (3)  (15)  (11)  (74)
     Net loss  (13,885)  (10,315)  (35,118)  (30,608)
Other comprehensive loss:                
 Unrealized gain (loss) on investments, net  (2)  (164)  (38)                  150 
Net change in other comprehensive loss  (2)  (164)  (38)                150 
Net loss and comprehensive loss $(13,887) $(10,479) $(35,156) $(30,458)
Net loss per share, basic and diluted $(0.40) $(0.31) $(1.02) $(0.94)
Weighted average common shares used to compute
net loss per share, basic and diluted
  34,736,015   33,757,599   34,536,980   32,597,007 
Balance Sheets Data
(Unaudited, in thousands)
       September 30, 2021 December 31, 2020
Current assets    
 Cash and cash equivalents $105,642  $69,466 
 Short-term investments  17,127   78,016 
 Accounts receivable, net  10,976   9,070 
 Inventories  16,049   9,989 
 Prepaid expenses and other current assets  4,662   6,787 
     Total current assets  154,456   173,328 
 Property and equipment, net  5,132   2,844 
 Restricted cash  232   310 
 Other non-current assets  5,711   2,832 
     Total assets $165,531  $179,314 
Liabilities and stockholders' equity    
Current liabilities    
 Accounts payable $4,908  $2,598 
 Accrued liabilities  16,011   16,957 
     Total current liabilities  20,919   19,555 
 Long-term debt  48,652   48,533 
 Other liabilities  7,781   3,726 
     Total liabilities  77,352   71,814 
Stockholders' equity    
 Preferred stock, $0.001 par value  -   - 
 Common stock, $0.001 par value  35   34 
Additional paid-in capital  362,152   346,318 
Accumulated other comprehensive income  1   39 
Accumulated deficit  (274,009)  (238,891)
     Total stockholders' equity  88,179   107,500 
     Total liabilities and stockholders' equity $165,531  $179,314